ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack
4.11.2025 18:00:00 CET | Business Wire | Press Release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/
ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack
Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications.
At Shopify, LibreChat has become central to internal AI workflows. “LibreChat powers reflexive AI use across Shopify. With near universal adoption and thousands of custom agents, teams use it to solve real problems, increase productivity, and keep the quality bar high. By connecting more than 30 internal MCP servers, it democratizes access to critical information across the company,” said Matt Burnett, Senior Engineer at Shopify.
In healthcare, cBioPortal uses the combined ClickHouse and LibreChat Agentic Data Stack to unlock new research capabilities. "By leveraging the ClickHouse, MCP, and LibreChat stack, we rapidly delivered a prototype to cBioPortal users that empowered them to ask entirely new questions about cancer genomics and treatment trajectories, get quick answers, and explore data in ways not possible through the existing UI," said Ino de Bruijn, Manager Bioinformatics Software Engineering at cBioPortal. "It puts discovery at cancer researchers' fingertips."
This LibreChat acquisition comes as enterprises rapidly adopt agentic analytics to democratize data access and accelerate time-to-insight. Fetch, a leading mobile rewards platform, built its FAST AI-powered analytics product on ClickHouse to transform household purchase behavior into actionable business intelligence. "We see agentic analytics as the future of data interaction, enabling more intuitive, dynamic, and impactful use of information," said Sam Corzine, Director of Machine Learning at Fetch. "With its unmatched speed and scalability, ClickHouse is well-positioned to power this new generation of agentic experiences, and we're thrilled to grow our partnership together."
ClickHouse leverages agentic analytics internally with LibreChat-and-ClickHouse-powered DWAINE (Data Warehouse AI Natural Expert), an agent that now handles approximately 70% of data warehouse queries for over 200 users, processing 33 million LLM tokens daily as of October 2025—up from 15 million just months after launch.
"What impressed me most is LibreChat's vibrant community that continuously innovates," said Dmitry Pavlov, Director of Engineering at ClickHouse. "The synergy between ClickHouse Cloud's blazing-fast query performance and LibreChat's flexible, multi-LLM architecture is unlocking a new generation of data analysis agents - real-time, secure, powerful, and accessible."
For existing LibreChat deployments, operations continue unchanged with ongoing investment in the open-source project and community. ClickHouse users will gain access to enhanced integration capabilities, including native LibreChat experience alongside ClickHouse Cloud instances, extended data visualization support, enterprise-grade security and governance, and a tailored semantic layer. These investments will ensure that the Agentic Data Stack is fully enterprise-ready, meeting the requirements of the world's most demanding organizations.
“Every breakthrough in data technology has been about reducing the distance between questions and answers. By joining forces with LibreChat, we’re tackling this distance. Now, any user can talk directly to petabytes of data and get instant, actionable insights,” said Aaron Katz, CEO of ClickHouse. “As AI agents proliferate across every industry, the companies that win will be those that can seamlessly connect human intelligence with machine-scale data processing. The future of analytics isn’t just dashboards, it’s intelligent agents that interpret data, trigger workflows, and power real-time decisions. The ClickHouse Agentic Data Stack makes that future available today.”
About ClickHouse
ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Anthropic, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.
About LibreChat
LibreChat is a leading open-source AI chat platform offering a unified interface for interacting with multiple large language models. The platform gives users and organizations complete control over their data, agents, and conversations while supporting enterprise-grade deployments at scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104505230/en/
Contacts
Tanya Bragin
ClickHouse, Inc.
tanya@clickhouse.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom